Uncategorized
IOP increase more likely in patients who receive large number of bevacizumab injections
BALTIMORE — Bevacizumab has a substantially increased risk of clinically relevant IOP increase in patients who have received more than 25 injections compared with ranibizumab or aflibercept, according to a “hot topic” designated study at the Association for Research in Vision and Ophthalmology annual meeting.“Looking at this in a real-world situation instead of the strict clinical research setting, what we found is a lower rate of clinically significant sustained IOP increase, so only 2% or 3% in patients overall, and it didn’t really vary between drugs except with patients who (Read more...)